De Vita, A.; Vanni, S.; Miserocchi, G.; Fausti, V.; Pieri, F.; Spadazzi, C.; Cocchi, C.; Liverani, C.; Calabrese, C.; Casadei, R.;
et al. A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences. Biomedicines 2022, 10, 372.
https://doi.org/10.3390/biomedicines10020372
AMA Style
De Vita A, Vanni S, Miserocchi G, Fausti V, Pieri F, Spadazzi C, Cocchi C, Liverani C, Calabrese C, Casadei R,
et al. A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences. Biomedicines. 2022; 10(2):372.
https://doi.org/10.3390/biomedicines10020372
Chicago/Turabian Style
De Vita, Alessandro, Silvia Vanni, Giacomo Miserocchi, Valentina Fausti, Federica Pieri, Chiara Spadazzi, Claudia Cocchi, Chiara Liverani, Chiara Calabrese, Roberto Casadei,
and et al. 2022. "A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences" Biomedicines 10, no. 2: 372.
https://doi.org/10.3390/biomedicines10020372
APA Style
De Vita, A., Vanni, S., Miserocchi, G., Fausti, V., Pieri, F., Spadazzi, C., Cocchi, C., Liverani, C., Calabrese, C., Casadei, R., Recine, F., Gurrieri, L., Bongiovanni, A., Ibrahim, T., & Mercatali, L.
(2022). A Rationale for the Activity of Bone Target Therapy and Tyrosine Kinase Inhibitor Combination in Giant Cell Tumor of Bone and Desmoplastic Fibroma: Translational Evidences. Biomedicines, 10(2), 372.
https://doi.org/10.3390/biomedicines10020372
